Bob, I agree the science is solid. In my searches for info and the links provided by others it is clear that researchers see something positive in BPI; however, that does not necessarily result in a new drug approval. Yes, this has something to do with the process, I know. I, along with others, was just trying to figure out why, with such a promising product, clearly outstanding clinicians working at the firm, and various tests in various phases, Xoma is not valued with its peers. The markets are fickle.
George, interest in short interest is this theory:
If short interest is extremely high or low, then stock price should rise or at least maintain a fairly level value. Rationale is when stock is heavily shorted and it goes down in price, shorts cover, causing stock price to rise. If stock is heavily shorted and stock starts to rise, shorts cover and add to momentum. It also serves as a contrarian indicator if a stock is heavily shorted at or near a low. |
